Literature DB >> 19325013

Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment.

Sherri L Kacinko1, Hendree E Jones, Rolley E Johnson, Robin E Choo, Marta Concheiro-Guisan, Marilyn A Huestis.   

Abstract

BACKGROUND: Buprenorphine (BUP) is under investigation as a medication therapy for opioid-dependent pregnant women. We investigated BUP and metabolite disposition in urine from women maintained on BUP during the second and third trimesters of pregnancy and postpartum.
METHODS: We measured BUP, norbuprenorphine (NBUP), buprenorphine glucuronide (BUP-Gluc), and NBUP-Gluc concentrations in 515 urine specimens collected thrice weekly from 9 women during pregnancy and postpartum. Specimens were analyzed using a fully validated liquid chromatography-mass spectrometry method with limits of quantification of 5 microg/L for BUP and BUP-Gluc and 25 microg/L for NBUP and its conjugated metabolite. We examined ratios of metabolites across trimesters and postpartum to identify possible changes in metabolism during pregnancy.
RESULTS: NBUP-Gluc was the primary metabolite identified in urine and exceeded BUP-Gluc concentrations in 99% of specimens. Whereas BUP-Gluc was identified in more specimens than NBUP, NBUP exceeded BUP-Gluc concentrations in 77.9% of specimens that contained both analytes. Among all participants, the mean BUP-Gluc:NBUP-Gluc ratio was significantly higher in the second trimester compared to the third trimester, and there were significant intrasubject differences between trimesters in 71% of participants. In 3 women, the percent daily dose excreted was higher during pregnancy than postpregnancy, consistent with other data indicating increased renal elimination of drugs during pregnancy.
CONCLUSIONS: These data are the first to evaluate urinary disposition of BUP and metabolites in a cohort of pregnant women. Variable BUP excretion during pregnancy may indicate metabolic changes requiring dose adjustment during later stages of gestation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325013      PMCID: PMC3166514          DOI: 10.1373/clinchem.2008.113712

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  31 in total

1.  Injecting misuse of buprenorphine among French drug users.

Authors:  Y Obadia; V Perrin; I Feroni; D Vlahov; J P Moatti
Journal:  Addiction       Date:  2001-02       Impact factor: 6.526

Review 2.  Clinical relevance of therapeutic drug monitoring during pregnancy.

Authors:  Ronen Loebstein; Gideon Koren
Journal:  Ther Drug Monit       Date:  2002-02       Impact factor: 3.681

3.  Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France.

Authors:  Gwenaëlle Vidal-Trecan; Isabelle Varescon; Norbert Nabet; Alain Boissonnas
Journal:  Drug Alcohol Depend       Date:  2003-03-01       Impact factor: 4.492

4.  The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols.

Authors:  S George; C George; M Chauhan
Journal:  Forensic Sci Int       Date:  2004-07-16       Impact factor: 2.395

5.  Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis.

Authors:  R E Bullingham; H J McQuay; E J Porter; M C Allen; R A Moore
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

6.  Analysis of buprenorphine and its N-dealkylated metabolite in plasma and urine by selected-ion monitoring.

Authors:  Y Blom; U Bondesson; E Anggård
Journal:  J Chromatogr       Date:  1985-02-27

7.  The metabolism and excretion of buprenorphine in humans.

Authors:  E J Cone; C W Gorodetzky; D Yousefnejad; W F Buchwald; R E Johnson
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

8.  63Ni electron-capture gas chromatographic assay for buprenorphine and metabolites in human urine and feces.

Authors:  E J Cone; C W Gorodetzky; D Yousefnejad; W D Darwin
Journal:  J Chromatogr       Date:  1985-02-08

9.  Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry.

Authors:  Robert Kronstrand; Tor G Seldén; Martin Josefsson
Journal:  J Anal Toxicol       Date:  2003-10       Impact factor: 3.367

10.  Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine.

Authors:  Sherri L Kacinko; Marta Concheiro-Guisan; Diaa M Shakleya; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2008-08-30       Impact factor: 4.142

View more
  9 in total

Review 1.  Effects of opioids on the parental brain in health and disease.

Authors:  James E Swain; S Shaun Ho; Helen Fox; David Garry; Susanne Brummelte
Journal:  Front Neuroendocrinol       Date:  2019-05-22       Impact factor: 8.606

2.  Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women.

Authors:  Marta Concheiro; Hendreé E Jones; Rolley E Johnson; Robin Choo; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

3.  Clearance of buprenorphine during pregnancy and neonatal outcomes.

Authors:  Jessica L Coker; Shona L Ray-Griffith; Cody McLeod; Xiaotong Han; Michael Mancino; Gregory L Kearns; Zachary N Stowe
Journal:  Arch Womens Ment Health       Date:  2021-04-16       Impact factor: 3.633

Review 4.  Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review.

Authors:  Hendrée E Jones; Sarah H Heil; Andjela Baewert; Amelia M Arria; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Gabriele Fischer
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

5.  Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation.

Authors:  Michael Z Liao; Chunying Gao; Brian R Phillips; Naveen K Neradugomma; Lyrialle W Han; Deepak Kumar Bhatt; Bhagwat Prasad; Danny D Shen; Qingcheng Mao
Journal:  Drug Metab Dispos       Date:  2017-11-20       Impact factor: 3.922

6.  Use of an Acetyl Derivative to Improve GC-MS Determination of Norbuprenorphine in the Presence of High Concentrations of Buprenorphine in Urine.

Authors:  Joel R Gervais; Gregory A Hobbs
Journal:  J Anal Toxicol       Date:  2016-01-25       Impact factor: 3.367

7.  Buprenorphine dosing for the treatment of opioid use disorder through pregnancy and postpartum.

Authors:  Caitlin E Martin; Caroline Shadowen; Bhushan Thakkar; Travis Oakes; Tamas S Gal; F Gerard Moeller
Journal:  Curr Treat Options Psychiatry       Date:  2020-07-28

8.  Opioid use disorder in pregnancy.

Authors:  Kristin Harter
Journal:  Ment Health Clin       Date:  2019-11-27

9.  Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?

Authors:  Darshan Shah; Stacy Brown; Nick Hagemeier; Shimin Zheng; Amy Kyle; Jason Pryor; Nilesh Dankhara; Piyuesh Singh
Journal:  Springerplus       Date:  2016-06-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.